Sugi Predict

Sugi Predict / Compounds / SCHEMBL608204

SCHEMBL608204

SCHEMBL608204

CS(=O)(=O)OC1CCN(Cc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ RECQL P46063 1/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.51
▸ ACHE P22303 2/20 0.50
▸ HTR2A P28223 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.49
▸ BCHE P06276 4/20 0.48
▸ DRD2 P14416 1/20 0.48
▸ BACE1 P56817 1/20 0.47
▸ MAOB P27338 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273941 1.00 SMN1; SMN2 (0.51) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL608203 1.00 SMN1; SMN2 (0.51) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL6279418 0.94 ALDH1A1 (0.57) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL28497475 0.92 BCHE (0.58) SMN1; SMN2RECQLHRH3ACHEALDH1A1
SCHEMBL19209909 0.92 BCHE (0.58) SMN1; SMN2RECQLHRH3ACHEALDH1A1
SCHEMBL5745231 0.92 BCHE (0.58) SMN1; SMN2RECQLHRH3ACHEALDH1A1
SCHEMBL5744278 0.91 HRH3 (0.59) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL5746137 0.88 FUCA1 (0.47) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL3890353 0.86 HRH3 (0.55) HRH3ACHEBCHEBACE1
SCHEMBL5184838 0.85 HRH3 (0.44) SMN1; SMN2RECQLHRH3ALDH1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
CN-119698412-A 5-HT2A receptor agonist, and preparation method and application thereof 上海翊石医药科技有限公司 2025-03-25 — — CN disclosed
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 — — WO disclosed
EP-3331886-A1 DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY Indivior UK Limited (GB) 2018-06-13 — — EP disclosed
WO-2017021920-A1 DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY INDIVIOR UK LIMITED (GB) 2017-02-09 — — WO disclosed
EP-1963304-B2 ISOQUINOLINE DERIVATIVES MSD OSS BV (NL) 2015-05-13 — — EP disclosed
US-8946422-B2 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2015-02-03 — — US disclosed
EP-2616071-A2 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-24 — — EP disclosed
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2013-07-04 — — US disclosed
CN-101945877-B Pyrrolopyrazine kinase inhibitors HOFFMANN LA ROCHE 2013-07-03 — — CN disclosed
US-6005119-A Process for preparing pyrrolidine derivatives KANEKA CORPORATION (JP) 1999-12-21 — — US disclosed
EP-0900787-A1 PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES KANEKA CORPORATION (JP) 1999-03-10 — — EP disclosed
EP-0863136-A1 Derivatives of azetidine and pyrrolidine Akzo Nobel N.V. (NL) 1998-09-09 — — EP disclosed
US-5466828-A Chiral 3-cyano-1-substituted-pyrrolidines WARNER-LAMBERT COMPANY (US) 1995-11-14 — — US disclosed
WO-1995001962-A1 PROCESS FOR THE PREPARATION OF CHIRAL 3-(1-AMINO-1,1-BISALKYLMETHYL)-1-SUBSTITUTED-PYRROLIDINES WARNER-LAMBERT COMPANY (US) 1995-01-19 — — WO disclosed
US-5347017-A Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines WARNER-LAMBERT COMPANY (US) 1994-09-13 — — US disclosed
US-5342846-A 7-substituted-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid compounds and 7-(substituted triazolyl pyrrolidin-1-yl) 4-oxoquinoline-3-carboxylic acid derivatives useful as antibacterial agents SYNPHAR LABORATORIES, INC. (CA) 1994-08-30 — — US disclosed
WO-1993024481-A1 7-SUBSTITUTED-6-FLUORO-1,4-DIHYDRO-4-OXO-QUINOLINE-3-CARBOXYLIC ACID COMPOUNDS AND RELATED COMPOUNDS AS ANTIBACTERIAL AGENTS SYNPHAR LABORATORIES, INC. (CA) 1993-12-09 — — WO disclosed
EP-0561850-A1 7-SUBSTITUTED-6-FLUORO-1,4-DIHYDRO-4-OXO-QUINOLINE-3-CARBOXYLIC ACID COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS SYNPHAR LABORATORIES INC. (CA) 1993-09-29 — — EP disclosed
WO-1992010492-A1 7-SUBSTITUTED-6-FLUORO-1,4-DIHYDRO-4-OXO-QUINOLINE-3-CARBOXYLIC ACID COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS SYNPHAR LABORATORIES, INC. (CA) 1992-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 SMN1; SMN2 4821/4885RECQL 4112/4885HRH3 4381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.